PRESS RELEASE

Berlin, March 10, 2025 – Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), Europe's leading publicly traded medical cannabis company, looks back on an extremely successful fourth quarter of 2024. With quarterly revenue of over EUR 20 million – including EUR 8.5 million in December alone – Cantourage recorded the strongest quarter in the company's history. Growth has continued into the new year: revenue amounted to EUR 7.0 million in January 2025 and rose to EUR 7.9 million in February.

Strong demand continues – production capacities are being expanded

‍Due to the continuing high demand for Cantourage products, production capacities will be further expanded. Cantourage has already initiated targeted measures to expand production capacities. Initial results from these initiatives are expected in the coming months.

Analysts show confidence in growth trajectory

Cantourage's dynamic business development has also been recognized by leading analysts. The research firms Montega and NuWays have adjusted their price targets for Cantourage shares: Montega to EUR 12.00 and NuWays to EUR 12.50.

‍

About Cantourage

Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol, and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022, and is traded under the ticker symbol “HIGH.”

‍

Press contact at Cantourage:

Manuel Taverne| taverne@cantourage.com

‍

This announcement does not constitute a public offering or an advertisement for a public offering for the sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).